In my opinion, investors need to be careful of the current MNKD stock run up. It’s likely it’s manipulation being pulled off by the warrant holders in order for them to cash out with good profit. Company has ZERO chance…
Tag: investing
Amarin Basic Company Thesis – Bearish 5/25/13 $AMRN
My basic opinion on Amarin. Like Vascepa, hate management and company structure. My opinion long term is bearish.
Biosciences Delivery Systems+ Antares Chart Update: 5/25/13 $BDSI, $ATRS
My opinion on Antares BDSI pasy trading action and for the future.
I bought BioDelivery Sciences (BDSI) on Bullish Chart: Solid Small Cap Spec Investment.
BioDelivery Sciences (BDSI) focuses on developing and commercializing products in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) and Bioral cochleate drug delivery technologies in the development of its products. …
I bought Antares @ $3.95, I see a move to $4.35 short term
I bought Antares @ $3.95, I see a move to $4.35 short term. I think from tomorrow to beginning of next week, we see the move. From above, we can clearly see a tightening wedge forming in the chart. I…
Insmed Chart technicals with my opinion and explanation: YouTube Video
Insmed Chart technicals with my opinion and explanation: YouTube Video below, enjoy!
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Rally Insmed
The Orphan Drug Act was passed in January 1983 to encourage companies to develop drugs that treat rare medical conditions. Companies that receive Orphan Drug Status gain certain financial incentives such as a longer period of exclusivity, enhanced patent protection,…
Updated: Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buy
Today, we are going to take a comprehensive look at a small-cap biotech company with several near-term catalysts, a strong cash position, and high insider ownership. I feel with all factors considered, this company can see very good price appreciation…
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
Today, we will take a detailed look into a company that has an imminent catalyst, a number of important Phase II and Phase III data releases throughout 2013, and a product pipeline with potential to tap into a $17B market.…
Weekend update with some charts, Market forecast and opinion. (VIDEO)
Weekend update with some charts, $AVEO $ATRS $ARNA $ACRX briefly covered. Market forecast and opinion. YouTube Video